Brokerages expect that DelMar Pharmaceuticals (NASDAQ:DMPI) will report earnings per share (EPS) of ($0.10) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for DelMar Pharmaceuticals’ earnings. DelMar Pharmaceuticals posted earnings per share of ($0.18) during the same quarter last year, which would indicate a positive year-over-year growth rate of 44.4%. The firm is expected to announce its next earnings results on Friday, May 11th.
On average, analysts expect that DelMar Pharmaceuticals will report full-year earnings of ($0.46) per share for the current financial year. For the next fiscal year, analysts expect that the business will post earnings of ($0.26) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that cover DelMar Pharmaceuticals.
Get DelMar Pharmaceuticals alerts:
DelMar Pharmaceuticals (NASDAQ:DMPI) last issued its quarterly earnings data on Thursday, February 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.01.
DelMar Pharmaceuticals stock traded up $0.02 during mid-day trading on Wednesday, reaching $0.97. 67,024 shares of the company traded hands, compared to its average volume of 486,224. The company has a market cap of $21.38 million, a P/E ratio of -1.31 and a beta of 1.46. DelMar Pharmaceuticals has a 52-week low of $0.96 and a 52-week high of $0.97.
DelMar Pharmaceuticals Company Profile
DelMar Pharmaceuticals, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in Phase III study for the treatment of recurrent glioblastoma multiforme.
Get a free copy of the Zacks research report on DelMar Pharmaceuticals (DMPI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com